TScan Therapeutics: Funding, Investors & Team (Oct 2026)
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
TScan Therapeutics has raised $310M across 4 funding rounds on record, the most recent an undisclosed round announced in Dec 2024.
TScan Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2024.
TScan Therapeutics Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
TScan Therapeutics raised $100M in a Series C announced in Jan 2021.
1.7 years later, a Debt Financing of $60.0M was announced in Sep 2022.
1.6 years later, an undisclosed round of $150M was announced in Apr 2024.
8 months later, an undisclosed round was announced in Dec 2024 with no disclosed amount.
TScan Therapeutics Founders and Leadership Team
Contact details for the TScan Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →TScan Therapeutics Funding Compared to Other Biotechnology Startups
Funded Startups Like TScan Therapeutics in Biotechnology and Waltham
Companies Similar to TScan Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
TScan Therapeutics Funding FAQs
What does TScan Therapeutics do?
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
How much funding has TScan Therapeutics raised?
TScan Therapeutics has raised $310M across 4 rounds on record.
When did TScan Therapeutics last raise funding?
TScan Therapeutics' most recent funding round on record was announced in Dec 2024. The amount was not disclosed.
Who founded TScan Therapeutics?
FundedIQ lists Tomasz Kula (Founder) at TScan Therapeutics.
Who is the CEO of TScan Therapeutics?
David Southwell is listed as CEO at TScan Therapeutics.
Where is TScan Therapeutics headquartered?
TScan Therapeutics is based in Waltham, Massachusetts, United States.
How many employees does TScan Therapeutics have?
TScan Therapeutics is in the 101-250 employee band.
About FundedIQ's TScan Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for TScan Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.